Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT03291379 Completed - Clinical trials for Metastatic Colorectal Cancer

Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies

VEROnA
Start date: May 17, 2017
Phase: Early Phase 1
Study type: Interventional

This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.

NCT ID: NCT03289533 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

Start date: September 8, 2017
Phase: Phase 1
Study type: Interventional

To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC

NCT ID: NCT03289273 Completed - Liver Neoplasms Clinical Trials

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

Start date: September 13, 2017
Phase:
Study type: Observational

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

NCT ID: NCT03285867 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma

Start date: June 25, 2018
Phase:
Study type: Observational

Objective: To evaluate the efficacy of preoperative liver stiffness measurement(LSM) by FibroScan in predicting the progress of liver fibrosis and prognosis after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Background: Progress of liver fibrosis and liver failure and related poor prognosis after TACE which are not completely predictable by current method including Child-Pugh Classification. LSM is used to calculate the degree of liver fibrosis and is affected by several liver injury, e.g. elevated Alanine aminotransferase(ALT), Aspartate transaminase(AST) and Bilirubin et al. The investigators assume that LSM could be use to predict progress of liver fibrosis and adverse effects after TACE in HCC. Methods: At least 200 patients will be recruited in this prospective observational study with preoperative LSM, demographic, laboratory, radiological and other treatment-related factors. Participants will be followed up till death or to the end of study no matter the liver failure occurs or not. Data will be analyzed to build a mathematical predicting model. Research hypothesis:TACE is related to progress of liver fibrosis and a mathematical model with LSM is able to predict the risk of liver failure and prognosis in HCC.

NCT ID: NCT03283956 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan

SERENADE-T
Start date: September 13, 2017
Phase: N/A
Study type: Observational

To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.

NCT ID: NCT03278444 Recruiting - HCC Clinical Trials

Treatment of Advanced Hepatocellular Carcinoma

TAHCC
Start date: July 18, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of arginine hydrochloride combined with trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.

NCT ID: NCT03277716 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study was to prospectively evaluate the efficacy and safety of TACE combined with MWA in patients with huge unresectable hepatocellular carcinoma.

NCT ID: NCT03275376 Terminated - Overall Survival Clinical Trials

Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma

Start date: December 21, 2017
Phase: Phase 2
Study type: Interventional

Target therapy with sorafenib is the standard of treatment for advanced Hepatocellular carcinoma (HCC), but the patient survival time is still unsatisfactory. The aims of this study are to prove statins improve the tumor responses and overall survival for patients who receive sorafenib therapy for advanced HCC by a prospective randomized controlled study.

NCT ID: NCT03274427 Recruiting - HCC Clinical Trials

Treatment of Intermediate-stage Hepatocellular Carcinoma

TIHCC
Start date: July 18, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with arginine hydrochloride and trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.

NCT ID: NCT03273608 Recruiting - Clinical trials for Hepatocellular Carcinoma

Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients

Start date: September 14, 2016
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this multicenter registry is to gather the safety, efficacy and survival data in intermediate and advanced HCC patients treated drug-eluting microsphere in Taiwan in order to provide clinical evidence in HCC management to physicians in the region, and to support the application of deTACE in treating advanced HCC patients.